At ErythroSight (a spinout being incubated at ANU and Clear Vision Research), we are developing next-generation therapeutics for the treatment of retinal- and neuro-degenerations. Using Red Blood Cell Derived Extracellular Vesicles (RBC-EVs), we are developing a safe, inexpensive and personalised blood-derived product to treat Age-related Macular Degeneration (AMD), the number one cause of irreversible blindness in the developed world.
Company Details
- Employees
- 2
- Founded
- -
- Address
- 131 Garran Rd, Acton,australian Capital Territory 2601,australia
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Acton, Australian Capital Territory
Erythrosight Questions
Erythrosight's website is https://www.clearvisionresearch.com/erythrosight
Erythrosight's LinkedIn profile is https://au.linkedin.com/company/erythrosight
Erythrosight has
2 employees.
View email and phone details for 2
employees at Erythrosight.
Erythrosight's industry is
Biotechnology Research
Erythrosight's top competitors are
Geneseq Biosciences,
Wintermute Biomedical Pty Ltd,
Topicure,
Cytophenix,
Incipiam Pharma,
Pollenizer,
Wild Yeast Zoo,
Loxegen,
Infinite Bioworks,
Embark Laboratories.
Erythrosight's categories are Biotechnology Research
Erythrosight's founding year is 2023
